Cytogen reports improved imaging with Prostascint

New York, June 7 - Cytogen Corp. said a series of studies using its Prostascint (capromab pendetide) indicated the potential for improved detection of disease using nuclear medicine imaging.

Prostascint is the only commercial monoclonal antibody-based agent that targets prostate-specific membrane antigen to image the extent and spread of prostate cancer, the company said.

Research on the use of the molecule was presented at the annual meeting of the Society of Nuclear Medicine in San Diego.

"Advances in nuclear medicine imaging, such as the integration of anatomical and functional imaging, hastened the growth and widespread adoption of positron emission tomography imaging," said Michael Becker, president and chief executive officer of Cytogen, in a news release.

"Similar advances are now being utilized in Spect [single-photon emission computed tomography] imaging with novel molecular imaging agents such as Prostascint as evidenced by the improved imaging quality reported by multiple centers at the SNM [Society of Nuclear Medicine] meeting.

"As with PET, these advances show the potential of fusion imaging with Prostascint to improve outcomes for patients and demonstrated important technical and clinical advantages."

Fusion imaging with Prostascint combines anatomic images with functional images. Anatomical information derived from either computed tomography or magnetic resonance imaging can be fused (or co-registered) with functional information obtained using single-photon emission computed tomography and novel molecular imaging agents such as Prostascint.

Single-photon emission computed tomography imaging focuses on metabolic abnormalities that may be present earlier than the anatomical changes otherwise seen with computed tomography or magnetic resonance imaging alone.

Co-registering anatomic and functional images provides an anatomic context for areas of enhanced or abnormal uptake, helping physicians identify areas of disease through enhanced image quality thereby enabling them to better plan an individualized treatment protocol for patients.

Cytogen is a Princeton, N.J.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.